RMTG (Regenerative Medical Technology Group) Moat Score: 1/10 (As of Jul. 05, 2026)


What is Regenerative Medical Technology Group Moat Score?

Regenerative Medical Technology Group RMTG -25.42% Moat Score is 1 as of Jul. 05, 2026. The stock has 4 warning signs investors should review. Among 1,395 Biotechnology companies, Regenerative Medical Technology Group ranks worse than 52.4% on this metric.

Regenerative Medical Technology Group has the Moat Score of 1, which implies that the company might have No Moat - Very weak/transient advantages.

Regenerative Medical Technology Group has No Moat: Regenerative Medical Technology Group Inc operates in a highly competitive sector with no significant intellectual property or brand strength. The company lacks durable cost advantages or significant regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Regenerative Medical Technology Group might have No Moat - Very weak/transient advantages.

Regenerative Medical Technology Group  (OTCPK:RMTG) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Regenerative Medical Technology Group Moat Score Related Terms

RMTG vs PTIX, CERO, EMMA: Moat Score Comparison

For the Biotechnology subindustry, Regenerative Medical Technology Group's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenerative Medical Technology Group Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenerative Medical Technology Group's Moat Score distribution charts can be found below:

* The bar in red indicates where Regenerative Medical Technology Group's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 1 mean?
Regenerative Medical Technology Group (RMTG) has a Moat Score of 1 as of Jul. 05, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Regenerative Medical Technology Group ranks #731 out of 1395 companies in the Biotechnology industry, placing it in the top 52.4%.
Is Regenerative Medical Technology Group's Moat Score too high?
Regenerative Medical Technology Group's current Moat Score is 1. The Biotechnology industry median Moat Score is 2.00. Regenerative Medical Technology Group's value of 1 is 50% below this industry median. Based on the distribution chart, Regenerative Medical Technology Group ranks #731 out of 1395 companies in the Biotechnology industry, which is below the industry midpoint.
How does Regenerative Medical Technology Group's Moat Score compare to PTIX and CERO?
According to the Biotechnology industry distribution chart, Regenerative Medical Technology Group ranks #731 out of 1395 companies for Moat Score. This places Regenerative Medical Technology Group in the lower half of its industry. The industry median Moat Score is 2.00. Regenerative Medical Technology Group's value of 1 is 50% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regenerative Medical Technology Group's current Moat Score of 1 is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenerative Medical Technology Group's current Moat Score is 1. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Possible Value Trap. The stock's GF Value™ is $0.06, compared to a current price of $0.02 — trading 63.3% below its estimated fair value. The current Moat Score is 1 and 50% below the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current Moat Score is 1 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerative Medical Technology Group Business Description

Address 433 Plaza Real, Suite 275, Boca Raton, FL, USA, 33432
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.